Αρχική World News FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection World News FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection Από Ogkologos - 14 Ιανουαρίου, 2026 464 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Experimental mRNA Vaccine Hints at Potential Against Glioblastoma 11 Ιουνίου, 2024 Can a Biopsy Make My Cancer Spread? 18 Μαρτίου, 2021 Do Birth Control Pills Impact My Cancer Risk? 20 Οκτωβρίου, 2022 Enhancements to NCI’s SEER Program Creating New Research Opportunities 23 Αυγούστου, 2018 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21... Study Identifies Potential Warning Signs of Colorectal Cancer in Younger Adults EMA Recommends Extension of Indications for Ribociclib to Include Use in...